Amgen Sharply Higher After Q4 Beat, Positive Repatha Results

Amgen, Inc. AMGN shares are trading higher by $6.42 at $166.00 in Friday's session.

The company gave investors a double dose of good news with a Q4 EPS beat of a dime and a sales beat of $25 million. The company announced Repatha has met its primary endpoint by reducing risks of cardiovascular events.

After a higher open, it continued in that direction before peaking at $167.85 and reversing course. That high just exceeds its October 10 high of $167.82.

From a longer-term perspective, the issue has held up much better than its peers in the biotech sector as it's near its all-time high that was made in July 2015 at $181.81. Many other issues in the sector are at 52-week and in some cases multi-year lows.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!